SCHEMBL2017203

SCHEMBL2017203

NC(=O)[C@H]1CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883675 1.00
SCHEMBL715019 1.00
SCHEMBL29621847 0.98
Hydrochloric Acid SCHEMBL4173444 0.98
Hydrochloric Acid SCHEMBL4717526 0.98 KMT2A (0.72)
Hydrochloric Acid SCHEMBL4714834 0.98 KMT2A (0.72)
Hydrochloric Acid SCHEMBL3403055 0.98
Hydrochloric Acid SCHEMBL3398658 0.98
Hydrochloric Acid SCHEMBL14311790 0.98 KMT2A (0.72)
Trifluoroacetic Acid SCHEMBL23779156 0.86 KDM4E (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
WO-2025090465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-05-01 WO disclosed
EP-4532487-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME Sanofi US Services Inc. (US) 2025-04-09 EP disclosed
CN-119301115-A Compounds for enhancing read-through of genes containing premature stop codons and methods of making and using the same 赛诺菲美国服务公司 2025-01-10 CN disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
US-12116343-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-15 US disclosed
EP-4351560-A1 ANTICANCER COMPOUNDS The Regents of the University of California (US) 2024-04-17 EP disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 CN disclosed
WO-2023235384-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2023-12-07 WO disclosed
WO-2023235384-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2023-12-07 WO disclosed
WO-2011145718-A1 NOVEL PYRROLO[2,3-D]PYRIMIDINE COMPOUND 田辺三菱製薬株式会社 (JP) 2011-11-24 WO disclosed
WO-2011073269-A1 PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS EVOTEC AG (DE) 2011-06-23 WO disclosed
WO-2010141538-A1 BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2010-12-09 WO disclosed
US-20100197908-A1 Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-05 US disclosed
EP-2144909-A1 [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS Novartis Ag (CH) 2010-01-20 EP disclosed
WO-2008122615-A1 [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2008-10-16 WO disclosed
US-20080234263-A1 Quinazoline Derivatives ASTRAZENECA (SE) 2008-09-25 US disclosed
EP-1877404-A2 NOVEL CYCLIC AMINES F. Hoffmann-Roche AG (CH) 2008-01-16 EP disclosed
WO-2007121124-A2 HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES NOVARTIS AG (CH) 2007-10-25 WO disclosed
WO-2006114401-A2 NOVEL CYCLIC AMINES F. HOFFMANN-LA ROCHE AG (CH) 2006-11-02 WO disclosed